X4 Pharmaceuticals (XFOR) Liabilities and Shareholders Equity (2017 - 2025)

X4 Pharmaceuticals' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $290.5 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 98.34% year-over-year to $290.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $689.2 million (up 6.46% YoY) and the FY2025 annual result came in at $290.5 million, up 98.34% from the prior year.
• Liabilities and Shareholders Equity was $290.5 million for Q4 2025 at X4 Pharmaceuticals, up from $163.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $290.5 million in Q4 2025 and bottomed at $81.0 million in Q2 2022.
• A 5-year average of $147.2 million and a median of $144.1 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 114.02% — and 2025, when it tumbled 50.07%.
• X4 Pharmaceuticals' Liabilities and Shareholders Equity stood at $117.2 million in 2021, then surged by 32.78% to $155.6 million in 2022, then slipped by 5.35% to $147.3 million in 2023, then slipped by 0.55% to $146.4 million in 2024, then soared by 98.34% to $290.5 million in 2025.
• Business Quant data shows XFOR's Liabilities and Shareholders Equity at $290.5 million in Q4 2025, $163.6 million in Q3 2025, and $105.2 million in Q2 2025.